Hodgkin's lymphoma: who needs consolidation treatment?
Mené en Amérique du Nord et en Europe sur 329 patients atteints d'un lymphome hodgkinien récidivant ou réfractaire, cet essai randomisé évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du brentuximab vedotin en traitement de consolidation après une greffe autologue de cellules souches
The introduction of multidrug chemotherapy and small-field radiation has substantially improved the prognosis of patients with Hodgkin's lymphoma, with long-term tumour control of 70–80% and overall survival of 80–90%. However, for patients who relapse the prognosis is poor, and fewer than 50% survive long term. High-dose chemotherapy followed by autologous stem-cell transplantation is the treatment of choice for most of these patients. By contrast, more than 90% of patients who relapse after autologous stem-cell transplantation die, with a median prognosis of 1·3 years.
The Lancet , commentaire, 2014